Pharmicell
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Pharmicell is a South Korean biopharmaceutical company listed on KOSPI, best known for developing the world's first approved stem-cell therapy for heart-attack patients.
Its Biomedical division develops stem-cell treatments, stores adult stem cells for clients, and supplies cosmetics containing stem-cell culture extracts. Its Biochemical division produces specialty chemicals including electronic materials with low dielectric properties, pharmaceutical intermediates such as Nucleoside and mPEG, and eco-friendly flame retardants for textiles and electronics, and this division accounts for the large majority of the company's total revenue.
Summary is AI-generated and may contain errors · figures from DART filings
The Biochemical division was created after Pharmicell absorbed a precision-chemicals subsidiary through a merger, making it an unusual hybrid of biopharma and specialty chemicals under one roof.
Pharmicell in five facts
What does Pharmicell do?
Pharmicell is a South Korean biopharmaceutical company listed on KOSPI, best known for developing the world's first approved stem-cell therapy for heart-attack patients.
Where is Pharmicell listed and in which sector?
Pharmicell (Korean name: 파미셀) trades under KRX code 005690 on KOSPI, the main board of the Korea Exchange. It is classified in the Information Technology sector, Components.
How large is Pharmicell?
Its market capitalisation was US$481.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Pharmicell's latest annual revenue and operating profit?
For fiscal year 2025, Pharmicell reported revenue of US$86.1M, operating profit of US$25.9M and net income of US$30.4M, per its annual report on DART (data retrieved from DART on 2026-06-04). Revenue was up 75.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-04
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Supply contract signed
Pharmicell disclosed a supply contract with Doosan, worth US$5.52M, about 6.49% of its recent annual revenue, running through Dec 2026.
Supply contract · Oct 14 - Investor relations (IR) meeting (notice)Oct 12
- Report on large shareholdings (5% rule) (standard)Oct 8
- Supply contract signed
Pharmicell disclosed a supply contract with Doosan, worth US$5.55M, about 6.92% of its recent annual revenue, running through Oct 2026.
Supply contract · Aug 7 - Supply contract signed
Pharmicell disclosed a supply contract with DOOSAN ELECTRO MATERIALS (CHANGSHU)CO.,LTD., worth US$4.65M, about 6.13% of its recent annual revenue, running through Jul 2026.
Supply contract · May 27 - Supply contract signed
Pharmicell disclosed a supply contract with Doosan Corporation Electronics BG, worth US$5.55M, about 7.08% of its recent annual revenue, running through Jul 2026.
Supply contract · May 8 - Cash/in-kind dividend decision
Pharmicell declared a cash dividend of US$0.03 per share.
Dividend · Feb 24 - Supply contract signed
Pharmicell disclosed a supply contract with Doosan Corporation Electronics BG, worth US$6.39M, about 14.18% of its recent annual revenue, running through Apr 2026.
Supply contract · Feb 19 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Pharmicell reported separate results for FY2025: revenue of US$78M (+75.8% year on year), operating profit of US$23.5M (+637.6% year on year) and net income of US$27.6M (+536.9% year on year).
Earnings · Feb 9